H pylori regimen
Reading File
H. pylori eradication uses triple or quadruple antibiotic regimens combined with a proton pump inhibitor (PPI). First-line options include clarithromycin-based triple therapy or bismuth quadruple therapy. Salvage regimens use levofloxacin or rifabutin. Duration is typically 14 days for best efficacy.
Searching sources...
Finding Sources
Searching PubMed
"Helicobacter pylori" AND eradication AND treatment
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive data from Harrison's and Yamada's to construct a thorough answer.
H. pylori Eradication Regimens
Who to Treat
Eradication is indicated in:
- Peptic ulcer disease (active or past) - regardless of NSAID use
- Gastric MALT lymphoma (60-90% achieve complete remission)
- After resection of early gastric cancer
- Uninvestigated dyspepsia (ACG: age <60 years; test-and-treat if local prevalence >20%)
- First-degree relatives of gastric cancer patients
- Long-term NSAID users (especially with prior PUD history)
- Unexplained vitamin B12 deficiency
First-Line Regimens
The choice depends on local clarithromycin resistance rates (<15% = low, >15% = high) and prior macrolide exposure.
1. Clarithromycin Triple Therapy
Use only if clarithromycin resistance <15% AND no prior macrolide exposure
| Drug | Dose | Frequency |
|---|---|---|
| PPI (any standard dose) | Omeprazole 20 mg / Pantoprazole 40 mg / Esomeprazole 40 mg / Lansoprazole 30 mg / Rabeprazole 20 mg | BID |
| Clarithromycin | 500 mg | BID |
| Amoxicillin | 1 g | BID |
| (Or metronidazole 500 mg TID if penicillin allergy) |
Duration: 14 days | Eradication rate: 75-90%
2. Bismuth Quadruple Therapy (BQT)
Now often recommended as first-line, particularly where clarithromycin resistance is high
| Drug | Dose | Frequency |
|---|---|---|
| PPI | Standard dose | BID |
| Bismuth subcitrate | 120-300 mg | QID |
| (or Bismuth subsalicylate) | 300 mg | QID |
| Tetracycline | 500 mg | QID |
| Metronidazole | 250-500 mg | QID/TID |
Duration: 10-14 days | Eradication rate: 85-90%
3. Concomitant (Non-bismuth) Quadruple Therapy
Alternative when bismuth unavailable; all 4 drugs given simultaneously
| Drug | Dose | Frequency |
|---|---|---|
| PPI | Standard dose | BID |
| Clarithromycin | 500 mg | BID |
| Amoxicillin | 1 g | BID |
| Metronidazole/Tinidazole | 500 mg | BID |
Duration: 10-14 days | Eradication rate: ~90%
4. Sequential Therapy (alternative non-bismuth quadruple)
- Days 1-5: PPI + Amoxicillin 1 g BID
- Days 6-10: PPI + Clarithromycin 500 mg + Metronidazole 500 mg (all BID)
5. Hybrid Therapy (alternative)
- Days 1-7: PPI + Amoxicillin 1 g BID
- Days 8-14: PPI + Amoxicillin 1 g + Clarithromycin 500 mg + Metronidazole 500 mg (all BID)
Second-Line (Salvage) Regimens
If initial eradication fails, avoid re-using clarithromycin if it was used first-line.
| Regimen | Drugs | Duration |
|---|---|---|
| Levofloxacin triple | PPI + Levofloxacin 500 mg + Amoxicillin 1 g (all BID) | 10 days |
| Bismuth quadruple (if not used 1st line) | PPI + Bismuth + Tetracycline + Metronidazole | 10-14 days |
| Rifabutin triple | PPI + Rifabutin 150 mg + Amoxicillin 1 g (BID) | 10 days - ~86% cure in resistant strains |
Third-line: Culture and sensitivity testing strongly recommended before choosing agents.
Key Points
- 14 days outperforms 7-10 days; do not shorten
- Clarithromycin resistance is the #1 cause of treatment failure - rates >50% in some countries
- Metronidazole resistance is common (30% in North America, up to 80% in developing countries) but triple therapy still achieves >50% eradication even with resistant strains
- Amoxicillin and tetracycline resistance remain rare (<1-2%)
- Confirm eradication with urea breath test or stool antigen at least 4 weeks after completing treatment and 2 weeks after stopping PPI
- Probiotics as adjunct may reduce antibiotic-related side effects
- Side effects affect 20-30% of patients on triple therapy
Antibiotic Selection Summary by Resistance Context
| Clarithromycin Resistance | Recommended First-Line |
|---|---|
| Low (<15%), no prior macrolides | Clarithromycin triple (14 days) OR bismuth quadruple |
| High (>15%) or unknown | Bismuth quadruple (first choice) or concomitant quadruple |
| Metronidazole also high | Bismuth + tetracycline + alternative antibiotic |
Sources: Harrison's Principles of Internal Medicine 22E (2025), pp. 2570-2571; Yamada's Textbook of Gastroenterology 7e, Chapter 49
Recent evidence note: A 2025 meta-analysis (PMID 39824392) confirms eradication therapy significantly reduces gastric cancer risk. A 2024 AGA expert review (PMID 39269391) also highlights potassium-competitive acid blockers (P-CABs) as emerging alternatives to PPIs in H. pylori regimens, potentially improving acid suppression and eradication rates.
This is a shared conversation. Sign in to Orris to start your own chat.